SSR180711, a novel selective α7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia

Neuropsychopharmacology

Volumn 32, Issue 1, 2007, Pages 17-34

  Pichat, Philippe ^a   Bergis, Olivier E ^a   Terranova, Jean Paul ^a   Urani, Alexandre ^a   Duarte, Christine ^a   Santucci, Vincent ^a   Gueudet, Christiane ^a   Voltz, Carole ^a   Steinberg, Régis ^a   Stemmelin, Jeanne ^a   Oury Donat, Florence ^a   Avenet, Patrick ^a   Griebel, Guy ^a   Scatton, Bernard ^a  

^a SANOFI   (France)

Author keywords

Alpha 7; Cognitive deficit; Memory; Nicotinic receptor; Partial agonist; Schizophrenia

Indexed keywords

4 BROMOPHENYL 1,4 DIAZABICYCLO[3.2.2]NONANE 4 CARBOXYLATE; ANTIDEPRESSANT AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; DIZOCILPINE; DOPAMINE; METHYLLYCACONITINE; NEUROLEPTIC AGENT; PHENCYCLIDINE; SSR 180711;

AMNESIA; ANIMAL EXPERIMENT; ARTICLE; BRAIN NERVE CELL; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DOPAMINE BRAIN LEVEL; DRUG ACTIVITY; DRUG EFFICACY; DRUG SELECTIVITY; ELECTROPHYSIOLOGY; EXPERIMENTAL MODEL; FEMALE; FORCED SWIMMING TEST; LEARNING; MALE; MATERNAL DEPRIVATION; MEMORY; MOUSE; NEUROCHEMISTRY; NONHUMAN; PREFRONTAL CORTEX; PREVALENCE; PRIORITY JOURNAL; RAT; RECOGNITION; SCHIZOPHRENIA; SELECTIVE ATTENTION; STRESS; TACHYPHYLAXIS; VOCALIZATION;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; BEHAVIOR, ANIMAL; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; FEMALE; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NICOTINIC AGONISTS; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; RECOGNITION (PSYCHOLOGY); SCHIZOPHRENIA;

EID: 33845719612     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301188     Document Type: Article

References (74)

1. Adler LE, Hoffer LD, Wiser A, Freedman R (1993). Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 150: 1856-1861.
2. Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K et al (1998). Schizophrenia, sensory gating, and nicotinic receptors. Schizophrenia Bull 24: 189-202.
3. Aggleton JP, Brown MW (1999). Episodic memory, amnesia, and the hippocampal-anterior thalamic axis. Behav Brain Sci 22: 425-489.
4. Aggleton JP, Pearce JM (2001). Neural systems underlying episodic memory: insights from animal research. Philos Trans R Soc Lond B Biol Sci 356: 1467-1482.
5. Allen RM, Young SJ (1978). Phencyclidine-induced psychosis. Am J Psychiatry 135: 1081-1084.
6. Arendash GW, Sengstock GJ, Sanberg PR, Kem WR (1995). Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res 674: 252-259.
7. Barnes TR, Curson DA, Liddle PF, Patel M (1989). The nature and prevalence of depression in chronic schizophrenic in-patients. Br J Psychiatry 154: 488-491.
8. Biton B, Bergis OE, Galli F, Nedelec A, Lochead AW, Jegham S et al (submitted). SSR180711: a novel selective α7 nicotinic receptor partial agonist: (I) Binding and functional profiles. Neuropsychopharmacology (in press).
9. Bliss TV, Collingridge GL (1993). A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361: 31-39.
10. Brebion G, Smith MJ, Gorman JM, Malaspina D, Sharif Z, Amador X (2000). Memory and schizophrenia: differential link of processing speed and selective attention with two levels of encoding. J Psychiatr Res 34: 121-127.
11. Briggs CA, Anderson DJ, Brioni JD, Buccafusco JJ, Buckley MJ, Campbell JE et al (1997). Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol Biochem Behav 57: 231-241.
12. Buccafusco JJ (2004). Neuronal nicotinic receptor subtypes: defining therapeutic targets. Mol Interv 4: 285-295.
13. Bymaster FP, Shannon HE, Rasmussen K, DeLapp NW, Ward JS, Calligaro DO et al (1999). Potential role of muscarinic receptors in schizophrenia. Life Sci 64: 527-534.
14. Coyle JT (1996). The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 3: 241-253.
15. Crider A (1997). Perseveration in schizophrenia. Schizophrenia Bull 23: 63-74.
16. Curet O, Damoiseau G, Aubin N, Sontag N, Rovei V, Jarreau FX (1996). Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile. J Pharmacol Exp Ther 277: 253-264.
17. Damaj MI, Glassco W, Dukat M, Martin BR (1999). Pharmacological characterization of nicotine-induced seizures in mice. J Pharmacol Exp Ther 291: 1284-1291.
18. Elvevag B, Weinberger DR, Goldberg TE (2001). Short-term memory for serial order in schizophrenia: a detailed examination of error types. Neuropsychology 15: 128-135.
19. Ennaceur A, Delacour J (1988). A new one trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 31: 47-59.
20. Franceschini D, Paylor R, Broide R, Salas R, Bassetto L, Gotti C et al (2002). Absence of alpha7-containing neuronal nicotinic acetylcholine receptors does not prevent nicotine-induced seizures. Brain Res Mol Brain Res 31: 29-40.
21. Freedman R (2003). Schizophrenia. N Engl J Med 349: 1738-1749.
22. Freedman R, Adams CE, Leonard S (2000). The α7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. J Chem Neuroanatomy 20: 299-306.
23. Gardner CR (1985). Distress vocalization in rat pups. A simple screening method for anxiolytic drugs. J Pharmacol Methods 14: 181-187.
24. Goff D, Coyle JT (2001). The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158: 1367-1377.
25. Goldman-Rakic PS, Selemon LD (1997). Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophrenia Bull 23: 437-458.
26. Gotti C, Fornasari D, Clementi F (1997). Human neuronal nicotinic receptors. Prog Neurobiol 53: 199-237.
27. Grace AA (1991). Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41: 1-24.
28. Gray R, Rajan AS, Radcliffe KA, Yakehiro M, Dani JA (1996). Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 383: 713-716.
29. Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S et al (2004). Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 56: 301-307.
30. 1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Nat Acad Sci USA 99: 6370-6375.
31. Grottick AJ, Higgins GA (2000). Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task. Behav Brain Res 117: 197-208.
32. Hahn B, Shoaib M, Stolerman IP (2003). Attentional effects of nicotinic agonists in rats. Neuropharmacology 44: 1054-1067.
33. Hajos M, Hurst RS, Hoffmann WE, Krause M, Wall TM, Higdon NR et al (2005). The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 (N-((3R)-1-Azabicyclo(2.2.2)oct-3-yl)-4-chlorobenzamide hydrochloride) enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J Pharmacol Exp Ther 312: 1213-1222.
34. Harrison PJ, Lewis DA (2003). Neuropathology of schizophrenia. In: Hirsch SR, Weinberger D (eds). Schizophrenia. Blackwell Publishing: Oxford. pp 310-325.
35. Hashimoto K, Okamura K, Shimizu E, Iyo M (2004). Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs. Curr Med Chem-CNS Agents 4: 147-154.
36. Hyde TM, Crook JM (2001). Cholinergic systems and schizophrenia: primary pathology or epiphenomena? J Chem Neuroanat 22: 53-63.
37. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308.
38. Kapur S, Remington G (1996). Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153: 466-476.
39. Kem WR (2000). The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res 113: 169-181.
40. Kesner RP, Dakis M (1993). Phencyclidine disrupts acquisition and retention performance within a spatial continuous recognition memory task. Pharmacol Biochem Behav 44: 419-424.
41. Kitagawa H, Takenouchi T, Azuma R, Wesnes KA, Kramer WG, Clody DE et al (2003). Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 28: 542-551.
42. Krystal JH, D'Souza DC, Petrakis IL, Belger A, Berman RM, Charney DS et al (1999). NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry 7: 125-143.
43. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995). Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13: 9-19.
44. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA (2001). Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25: 455-467.
45. Levin ED, Bettegowda C, Blosser J, Gordon J (1999). AR-R17779, an alpha7 nicotinic agonist, improves learning and memory in rats. Behav Pharmacol 10: 675-680.
46. Levin ED, Rezvani AH (2002). Nicotinic treatment for cognitive dysfunction. Curr Drug Targets CNS Neurol Disord 1: 423-431.
47. Levin ED, Simon BB (1998). Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology 138: 217-230.
48. Lieberman JA, Sheitman BB, Kinon BJ (1997). Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 17: 205-229.
49. Lukoyanov NV, Lukoyanova EA, Andrade JP, Paul-Barbosa MM (2005). Impaired water maze navigation of Wistar rats with retrosplenial cortex lesions: effect of non spatial pretraining. Behav Brain Res 158: 175-182.
50. Martin LF, Kem WR, Freedman R (2004). Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology 174: 54-64.
51. Meltzer HY, McGurk SR (1999). The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25: 233-255.
52. Meyer EM, Tay ET, Zoltewicz JA, Meyers C, King MA, Papke RL et al (1998). Neuroprotective and memory-related actions of novel alpha-7 nicotinic agents with different mixed agonist/antagonist properties. J Pharmacol Exp Ther 284: 1026-1032.
53. Monaghan DT, Bridges RJ, Cotman CW (1989). The excitatory amino-acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol 29: 365-402.
54. Morris RG, Hagan JJ, Rawlins JN (1986). Allocentric spatial learning by hippocampectomised rats: a further test of the 'spatial mapping' and 'working memory' theories of hippocampal function. Q J Exp Psychol B 38: 365-395.
55. Olney JW, Farber NB (1995). Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52: 998-1007.
56. Orr-Urtreger A, Goldner FM, Saeki M, Lorenzo I, Goldberg L, De Biasi M et al (1997). Mice deficient in the alpha7 neuronal nicotinic acetylcholine receptor lack alpha-bungarotoxin binding sites and hippocampal fast nicotinic currents. J Neurosci 17: 9165-9171.
57. Paterson D, Nordberg A (2000). Neuronal nicotinic receptors in the human brain. Prog Neurobiol 61: 75-111.
58. Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates. Academic Press: Sydney.
59. Porsolt RD (1977). Historical perspective on CMS model. Psychopharmacology 134: 363-364.
60. Rossato JI, Bonini JS, Coitinho AS, Vianna MR, Medina JH, Cammarota M et al (2004). Retrograde amnesia induced by drugs acting on different molecular systems. Behav Neurosci 118: 563-568.
61. Sara SJ (1985). Noradrenergic modulation of selective attention: its role in memory retrieval. Ann NY Acad Sci 444: 178-193.
62. Sara SJ, Deweer B, Hars B (1980). Reticular stimulation facilitate retrieval of a forgotten maze habit. Neurosci Lett 18: 211-217.
63. Smith RC, Singh A, Infante M, Khandat A, Kloos A (2002). Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 27: 479-497.
64. Stevens KE, Kem WR, Mahnir VM, Freedman R (1998). Selective alpha 7 nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology 136: 320-327.
65. Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB et al (2003). N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-Daspartate receptor activity. Proc Natl Acad Sci USA 100: 13674-13679.
66. Svensson TH, Grenhoff J, Engberg G (1990). Effect of nicotine on dynamic function of brain catecholamine neurons. Ciba Found Symp 152: 169-180.
67. Taiminen TJ, Salokangas RK, Saarijarvi S, Niemi H, Lehto H, Ahola V et al (1998). Smoking and cognitive deficits in schizophrenia: a pilot study. Addict Behav 23: 263-266.
68. Tendolkar I, Weis S, Guddat O, Fernandez G, Brockhaus-Dumke A, Specht K et al (2004). Evidence for a dysfunctional retrosplenial cortex in patients with schizophrenia: a functional magnetic resonance imaging study with a semantic-perceptual contrast. Neurosci Lett 369: 4-8.
69. Terranova JP, Chabot C, Barnouin MC, Perrault G, Depoortere R, Griebel G et al (2005). SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit. Psychopharmacology 181: 134-144.
70. Van Kampen M, Selbach K, Schneider R, Schiegel E, Boess F, Schreiber R (2004). AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors. Psychopharmacology 172: 375-383.
71. Wang C, McInnis J, Ross-Sanchez M, Shinnick-Gallagher P, Wiley JL, Johnson KM (2001). Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience 107: 535-550.
72. Wang C, McInnis J, West JB, Bao J, Anastasio N, Guidry JA et al (2003). Blockade of phencyclidine-induced cortical apoptosis and deficits in prepulse inhibition by M40403, a superoxide dismutase mimetic. J Pharmacol Exp Ther 304: 266-272.
73. Weinberger DR (1986). The pathogenesis of schizophrenia: a neurodevelopmental theory. In: Nasrallah HAW, Weinberger DR (eds). The Neurology of Schizophrenia. Elsevier: Amsterdam. pp 397-406.
74. Willner P, Muscat R, Papp M (1992). Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev 16: 525-534.